论文部分内容阅读
美国马里兰州贝塞斯达市的国立癌症研究所(NCI)Boyd博士最近披露新的研究战略,即筛选抗癌药物的研究计划。由于用小鼠白血病细胞筛选扰癌药物存在各种问题,故在定向筛选途径方面,NCI的战略转向用人类肿瘤细胞株。在用于各种组织亚型肿瘤的基础上,又用一系列细胞株研究各种组织类型的肿瘤,因为即使同一组织类型的人体肿瘤,也具有相当不一致的化学药物敏感性。上述战略首先集中在肺癌的研究中,包括研究代表实体肿瘤主要亚型的细胞株在内。Shoemaker博士指出,一种自动分析法能克服大量细胞株研究的复杂性。NCI这一新概念,即用人类肿瘤细胞株筛选抗
Dr. Boyd of the National Cancer Institute (NCI) in Bethesda, Maryland, recently unveiled a new research strategy, a screening program for screening anticancer drugs. Since there are various problems in screening for cancer-suppressing drugs using mouse leukemia cells, NCI’s strategy is to use human tumor cell lines in the directional screening pathway. Based on a variety of tissue subtype tumors, a series of cell lines are used to study tumors of various tissue types because even human tumors of the same tissue type have rather inconsistent chemical drug sensitivity. The above strategies were first focused on the study of lung cancer, including the study of cell lines that represent major subtypes of solid tumors. Dr. Shoemaker pointed out that an automated analysis can overcome the complexity of the study of a large number of cell lines. The new concept of NCI, that is, screening with human tumor cell lines